News & Events

In this section

Advinus Therapeutics Increases Use of Instem's Preclinical Software Suite to Support Growth

Advinus Therapeutics increases Provantis user licenses by 40% at Bangalore facility to support growth in India Operations

CONSHOHOCKEN, PA - (BUSINESS WIRE) – January 27, 2012 - - Instem, a leading provider of early development software applications, announced today that Advinus Therapeutics (Advinus) has purchased additional Provantis® preclinical software user licenses for their 220,000 square foot  facility in Bangalore.
Advinus is a research-based Pharmaceutical company offering end-to-end development services to the global Pharmaceutical, Agrochemical and Biotech industries, while at the same time creating long-term value through internal and collaborative innovative Drug Discovery.

Instem has been proud to support Advinus since 2005 when they selected Instem’s integrated Provantis solution suite following a comprehensive competitive evaluation of preclinical systems on the market.

Key Facts

Dr. R. S. Rao, Head, Safety Assessment at Advinus comments, “We have been extremely impressed with Instem’s products and services as well as the knowledge, commitment and experience of the Instem team. The deployment of Instem solutions at our Bangalore site has been instrumental in helping us to attract more Western business, as well as further enhancing our client services and ensuring GLP compliance.”

Demand for regulatory toxicology services has grown within India in recent years, fueled by the internal investments of Indian pharmaceutical and chemical companies, the recent addition of India within the OECD Mutual Acceptance of Data program and the demand from elsewhere in the world for high-quality, cost-effective non-clinical services.

“Our partnership with Advinus has successfully developed over the years and we are delighted that they have committed to further roll out Provantis across their organization,” comments Neil Donaldson, Instem’s VP of Asian and European Operations.  “Given our presence in the region and our commitment to the Indian R&D community, we believe that Instem is ideally poised to support the important role that Indian organizations play in this increasingly competitive global market”.

About Advinus Therapeutics

Advinus Therapeutics is a research-based Pharmaceutical Company founded by leading global pharmaceutical executives and promoted by the TATA Group. The company is the first of its kind in India to offer end-to-end development services to the global Pharmaceutical, Agrochemical and Biotech industries and at the same time creating long-term value through internal and collaborative innovative Drug Discovery.

Advinus has three operational sites; Advinus Drug Discovery, which is located in a state of the art facility in Pune (near Mumbai) and the Advinus Pharmaceutical and Agrochemical development centers based in Bangalore.

Advinus’ vision is to emerge as the leading and most admired life sciences R&D company from India, creating value for its customers and stakeholders.

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

Meeting clients at the intersection of investment & return™.

Press Contacts:

Gary Mitchell (US HQ)
Tel: 610-941-0990

Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600